drugset
drugset / Trial / NCT04378569

Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema

NCT04378569 ↗

Phase 1/2 Completed 230 enrolled Arcutis Biotherapeutics, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will assess the safety and efficacy of ARQ-252 cream in subjects with chronic hand eczema

Timeline

Start
2020-04-20
Primary completion
2021-02-24
Completion
2021-02-24

Drugs

EvaluationDrugModalityDoseRoute
Comparator ARQ-252 Unknown 0.1 % —
Comparator ARQ-252 Unknown 0.3 % —

Indications

No indication recorded.